SCHEMBL18137673

SCHEMBL18137673

O=CNCc1nc(Br)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.37
ADH1C P00326 1/20 0.37
ADH1A P07327 1/20 0.37
ADH7 P40394 1/20 0.37
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3869526 0.78 CTSL (0.32)
SCHEMBL31214187 0.77 ERN1 (0.34) ADH1BADH1CADH1AADH7
SCHEMBL839538 0.72
SCHEMBL18397344 0.72
SCHEMBL22326459 0.71 KDM1A (0.46) ADH1BADH1CADH1AADH7
SCHEMBL13082139 0.71 CCR4 (0.30)
SCHEMBL18132263 0.71 LOXL2 (0.32)
SCHEMBL1864095 0.71 KDM4E (0.32)
SCHEMBL22345799 0.70 TRPV3 (0.49)
SCHEMBL22345802 0.70 TRPV3 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531693-B 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors 百济神州有限公司 2021-07-06 CN disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2020-05-12 US disclosed
CN-110872289-A Novel 8-substituted imidazo [1,5-a ] pyridines as IDO1 and/or TDO inhibitors 百济神州(北京)生物科技有限公司 2020-03-10 CN disclosed
US-20190284184-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2019-09-19 US disclosed
US-10280163-B2 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases BEIGENE, LTD. (KY) 2019-05-07 US disclosed
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2018-03-15 US disclosed
WO-2016161960-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE, LTD. (KY) 2016-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280163-B2 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases IDO1, TPH1, IDO2 ADH1B 257/4885ADH1C 531/4885ADH1A 168/4885
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases IDO1, TPH1, IDO2 ADH1B 257/4885ADH1C 531/4885ADH1A 168/4885
US-20190284184-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES IDO1, TPH1, IDO2 ADH1B 246/4885ADH1C 521/4885ADH1A 135/4885
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES IDO1, TPH1, IDO2 ADH1B 257/4885ADH1C 519/4885ADH1A 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.